An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Latest Information Update: 18 Nov 2025
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms ECZTEND
- Sponsors LEO Pharma
Most Recent Events
- 21 Oct 2025 According to a Leo Pharma media release, data from this trial will be presented at the upcoming 2025 Fall Clinical Dermatology Conference
- 19 Sep 2025 According to a Leo Pharma media release, data from this trial presented at the European Academy of Dermatology and Venereology (EADV) Congress
- 19 Sep 2025 Results published in the Leo Pharma Media Release